Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mononuclear cells for pediatric dilated cardiomyopathy
IRCT20080728001031N27Phase 2Completed
- Sponsor
- Royan Institute
- Start
- Oct 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in dilated cardiomyopathy (DCM) (2 arms), sponsored by Royan Institute. Primary endpoint: Adverse events. Started Oct 2014; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on IRCT20080728001031N27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080728001031N27.